

---

***Financial Report 2021***

Stichting voor Lever en Maag-Darm  
Onderzoek

At ROTTERDAM, The Netherlands





## ***Compilation Statement***

The financial statements of Stichting voor Lever en Maag-Darm Onderzoek based in Rotterdam have been compiled by us using the information provided by you. The financial statements comprise the balance sheet as at 31 December 2021 and the statement of income and expenditure for the year 2021, with the accompanying explanatory notes. These notes include a summary of the accounting policies which have been applied.

This compilation engagement has been performed by us in accordance with Dutch law, including the Dutch Standard 4410, 'Compilation engagements', which is applicable to accountants. The standard requires us to assist you in the preparation and presentation of the financial statements in accordance with accounting principles as determined by the board of the foundation. To this end we have applied our professional expertise in accounting and financial reporting.

In a compilation engagement, you are responsible for ensuring that you provide us with all relevant information and that this information is correct. Therefore, we have conducted our work, in accordance with the applicable regulations, on the assumption that you have fulfilled your responsibility. To conclude our work, we have read the financial statements as a whole to consider whether the financial statements as presented correspond with our understanding of Stichting voor Lever en Maag-Darm Onderzoek.

We have not performed any audit or review procedures which would enable us to express an opinion or a conclusion as to the fair presentation of the financial statements.

During this engagement we have complied with the relevant ethical requirements prescribed by the 'Verordening Gedrags- en Beroepsregels Accountants' (VGBA, Dutch Code of Ethics). You and other users of these financial statements may therefore assume that we have conducted the engagement in a professional, competent and objective manner and with due care and integrity and that we will treat all information provided to us as confidential.

For further information on the nature and scope of a compilation engagement and the VGBA we refer you to [www.nba.nl/uitleg-samenstellingsverklaring](http://www.nba.nl/uitleg-samenstellingsverklaring).

Breda, 20<sup>th</sup> June 2022

216 Accountants B.V.

J.C. Hameetman AA

Breda

Reference number: 02060-22H327

Internal reference: 1000002060

## Report of the board for the year 2021

Rotterdam, 13<sup>th</sup> of June 2022,

Aim of the Foundation is to promote scientific research of gastrointestinal and liver disorders.

In 2020, due to the COVID -19 pandemic a part of the research was interrupted or stopped. Also, it was more difficult to find funding. Since 2021 most of the research is reinstated and new projects have been started. In 2021 new projects amount to EUR 1.398.000. For 2022 we hope to stay on this track.

In April 2021 Herold Metselaar retired and Manon Spaander has taken his place as chairman of the Foundation. In October Herold Metselaar has given his valedictory lecture with the title 'Thinking in possibilities'. After the lecture he received a Royal award for his effort in liver transplantation care, research, and education. A well-deserved award.

Caroline den Hoed has taken over his board membership and is now managing his cluster. In addition, Arjun Koch and Milan Sonneveld have joined the board. In 2021 there were 10 board members, each board member with its own cluster.

In order to be more in control on the type and number of projects and the prioritization the Executive Board together with the Coordinator of the Clinical Trial Bureau successfully reorganized the work processes. This resulted in reduced workload leaving more time for our Coordinator Nicole Larmonie to focus on the ongoing research projects and the start-up of new projects. The way it is now organized is also in line with the vision of the Erasmus MC.

A total of 205 peer reviewed articles have been published in international articles and 13 PhDs have finished their thesis in 2021. The Foundation has played a key role in this success.

In 2021 the 36th Erasmus Liver Days took place. A total of 289 participants attended the meeting. In both 2020 and 2021 the meeting was digital. The Erasmus Liver Day in 2022 will take place in conference center De Doelen again.

The Foundation is a financially healthy Foundation with ANBI-status. The Foundation will continue to invest in translational and clinical research of gastrointestinal and liver disorders.

The Board wants to express their gratitude to the Supervisory Board for their input and advice.

Manon Spaander, chairman

Rob de Knegt, treasurer

Andre Boonstra, secretary

**Balance sheet as at 31 December 2021**

(after appropriation of result)

	<u>2021</u>	<u>2020</u>
<b>Assets</b>		
	€	€
<b>Current assets</b>		
Research projects	4.843.515	4.295.409
Instalments on research projects	-7.400.129	-6.956.081
Accounts receivable	219.554	112.427
Cash at bank and in hand	3.555.847	3.978.068
	<u>1.218.787</u>	<u>1.429.823</u>
<b>Current liabilities</b>	-321.236	-509.521
<b>Working Capital</b>	<u>897.551</u>	<u>920.302</u>
<b>Foundation Equity</b>	<b>897.551</b>	<b>920.302</b>

## *Statement of income and expenditure 2021*

	<u>2021</u>	<u>2020</u>
	€	€
Revenue from investigations	1.841.231	1.870.913
Other income	-	130.381
Investigate change in capitalized costs in progress	104.058	-702.146
	<hr/>	<hr/>
<b>Sum of revenues</b>	<b>1.945.289</b>	<b>1.299.148</b>
Investigate direct costs	1.687.541	1.521.439
General expenses:		
- Personnel costs	181.544	237.109
- Other operating costs	84.979	76.102
	<hr/>	<hr/>
<b>Sum of costs</b>	<b><u>-1.954.064</u></b>	<b><u>-1.834.650</u></b>
<b>Operating result before interest</b>	<b>-8.775</b>	<b>-535.502</b>
Financial income and expenses	<u>-13.976</u>	<u>223</u>
<b>Net result</b>	<b>-22.751</b>	<b>-535.279</b>

## ***Notes to the annual accounts 2021***

### **Principles of valuation and determination of the result**

#### **ANBI status**

The Foundation for Liver Gastrointestinal Research has its registered office at 3065RD Rotterdam, Kralingsweg 369.

The Foundation aims to:

- a) promoting scientific research in the field of gastrointestinal and liver diseases, including diseases of the bile ducts, pancreas and oesophagus;
- b) promoting an adequate infrastructure for the specialism of Gastrointestinal and Liver Diseases and related surgery, mainly in the Erasmus MC and the Rotterdam region.

The Foundation has included in the ANBI register at the Dutch tax authorities

#### **General**

The annual accounts are drawn up on the basis of the accounting principles as chosen by the board of the foundation.

Tangible fixed assets are charged to a project directly or to the statement of income and expenditure.

Unless stated otherwise, all assets and liabilities are stated at nominal value.

Receivables and short-term debts are receivables and debts due within one year.

#### **Research projects in progress**

These are valued at attributable costs of third parties, attributable personnel costs and a surcharge for indirect costs.

In case of an expected loss on a research project, a provision is formed for the entire amount of the expected loss.

#### **Operating result**

The results on research projects (contributions and donations minus costs attributable to them) are recognized in the statement of income and expenditure according to the percentage of completion method. The revenue from research projects consists of contributions received on the completed projects, less revenues which have already been accounted for in previous years.

Taking into account of these accounting principles, the operating result is determined as difference between research revenues and attributable costs and other income and expenses in the year, determined on the basis of historical costs.

## Balance as at 31 December 2021

### Current assets

#### Research projects in progress

	<b>2021</b>	2020
	<b>EUR</b>	EUR
Costs projects in progress	6.010.402	5.333.755
Less: Provision for foreseen losses on projects	-1.166.887	-1.038.346
	<u>4.843.515</u>	<u>4.295.409</u>

The movements in the Costs projects in progress during the year can be specified as follows:

	<b>2021</b>	2020
	<b>EUR</b>	EUR
<b>Balance as at January 1</b>	<b>5.333.755</b>	<b>6.236.114</b>
<b>Research expenses:</b>		
Personnel costs	1.154.166	1.048.558
External research agencies	19.146	20.527
Laboratory costs	145.270	57.756
Travel expenses	23.817	15.992
Conferences	54.759	51.977
Phone/Internet	10.156	33.035
Purchase equipment	7.252	114.637
METC costs	61.309	43.638
Cost of bad debts		-
Miscellaneous expenses	211.666	135.319
	<u>1.687.541</u>	<u>1.521.439</u>
Allocated overhead expenses	202.507	181.499
	<u>1.890.048</u>	<u>1.702.938</u>
	<u>7.223.803</u>	<u>7.939.052</u>
Completed research projects	<u>-1.213.401</u>	<u>-2.605.297</u>
<b>Balance as at December 31</b>	<b>6.010.402</b>	<b>5.333.755</b>



**Instalments on projects**

This concerns instalments received from clients with respect to research projects that have not yet been completed. These amounts are released to the statement of income and expenditure under the heading "Revenue from research projects", according to the percentage of completion of the research project.

	<b>2021</b> <b>EUR</b>	2020 EUR
Invoiced instalments	7.830.561	7.319.027
Released due to statement of income and expenditure	-430.432	-362.946
	<u>7.400.129</u>	<u>6.956.081</u>

The movements in the Invoiced instalments during the year can be specified as follows:

	<b>2021</b> <b>EUR</b>	2020 EUR
<b><i>Balance as at January 1</i></b>		
Invoiced instalments	7.319.027	8.204.143
Released to statement of income and expenditure	-362.946	-362.657
	<u>6.956.081</u>	<u>7.841.486</u>

	<b>2021</b> <b>EUR</b>	2020 EUR
<b><i>Movements in the financial year</i></b>		
Invoiced instalments	1.841.231	1.870.913
Completed research projects	-1.329.697	-2.756.029
To statement of income and expenditure	-67.486	-289
	<u>444.048</u>	<u>-885.405</u>

	<b>2021</b> <b>EUR</b>	2020 EUR
<b>Balance as at December 31</b>		
Invoiced instalments	7.830.561	7.319.027
Released to statement of income and expenditure	-430.432	-362.946
	<u>7.400.129</u>	<u>6.956.081</u>

**Receivables and accruals**

	<b>2021</b>	2020
	<b>EUR</b>	EUR
Debtors	219.554	107.739
Accrued interest	-	684
VAT	-	4.004
	<u>219.554</u>	<u>112.427</u>

**Liquid assets**

	<b>2021</b>	2020
	<b>EUR</b>	EUR
ABN AMRO, Current account	10.674	7.329
ABN AMRO, Capital market index account	200.674	200.674
ABN AMRO, Bonus savings account	988.405	988.405
ABN AMRO, Business deposit	952.702	952.702
ABN AMRO, Support account	989	2.079
Rabobank, Current account	654.277	1.079.254
Rabobank, Savings account	748.126	747.625
	<u>3.555.847</u>	<u>3.978.068</u>

**Current liabilities**

	<b>2021</b>	2020
	<b>EUR</b>	EUR
Creditors	118.311	441.891
Accrued expenses	192.812	67.630
VAT	10.113	-
	<u>321.236</u>	<u>509.521</u>

**Foundation equity**

	<b>2021</b>	2020
	<b>EUR</b>	EUR
Balance as at Januari 1	920.302	1.455.581
Result for the year	-22.751	-535.279
Balance as at December 31	897.551	920.302

The foundation's equity consists of a General Reserve and cluster reserves related to active clusters within the foundation. The cluster reserves are at disposal of the respective clusters to be used autonomously for the costs of research projects to be initiated within the clusters. The positive or negative results of a year are allocated to the cluster's reserves as follows:

The movement of the cluster reserve is determined annually on the basis of the total of the positive or negative balances of the research projects within the cluster and consists partly of the General reserve of the Foundation's equity from the deficit/surplus on the allocated overhead expenses to projects.

The movements in 2021 are as follows:

	<b>As at</b>	<b>Movements</b>	<b>As at</b>
	<b>January 1</b>	<b>EUR</b>	<b>December 31</b>
	<b>EUR</b>	<b>EUR</b>	<b>EUR</b>
General	284.834	-77.993	206.841
Cluster 1	43.962	-188	43.774
Cluster 2	-	-	-
Cluster 3	1.926	92.687	94.613
Cluster 4	1.163	4.390	5.553
Cluster 5	164.289	-49.374	114.915
Cluster 6	40.456	155.990	196.446
Cluster 7	1.099	871	1.970
Cluster 8	230.425	-77.104	153.321
Cluster 9	-	189	189
Cluster 10	152.148	-72.219	79.929
	920.302	-22.751	897.551

## Statement of income and expenses 2021

### Direct costs

	<b>2021</b>	2020
	<b>EUR</b>	EUR
Personnel expenses	1.154.166	1.048.558
External research agencies	19.146	20.527
Laboratory expenses	145.270	57.756
Travel expenses	23.817	15.992
Conferences	54.759	51.977
Phone/Internet	10.156	33.035
Purchase equipment	7.252	114.637
METC costs	61.309	43.638
Miscellaneous expenses	211.666	135.319
	<b>1.687.541</b>	<b>1.521.439</b>

The personnel expenses are charged by Erasmus MC for personnel that has been deployed to research projects.

### Travel expenses

	<b>2021</b>	2020
	<b>EUR</b>	EUR
Study-related travel expenses	13.676	4.281
Travel expenses for professors for recruitment of new studies	1.766	-4.003
Travel expenses for staff members to attend conferences and presentation of the result studies	8.375	15.714
	<b>23.817</b>	<b>15.992</b>

### General expenses

#### Personnel expenses

	<b>2021</b>	2020
	<b>EUR</b>	EUR
Personnel expenses - indirect	180.401	235.249
Travel expenses	1.049	1.657
Canteen costs	94	203
	<b>181.544</b>	<b>237.109</b>

The personnel expenses are charged by Erasmus MC for personnel of the Clinical Research Bureau, which performs support and administrative tasks.

**Other operating costs**

	<b>2021</b>	2020
	<b>EUR</b>	EUR
Accounting expenses	60.000	60.000
Accountant fees	3.300	3.550
Other general expenses	21.679	12.552
	<hr/> 84.979	<hr/> 76.102

**Financial income and expenses**

	<b>EUR</b>	EUR
Interest expenses	<hr/> -13.976	<hr/> 223

## A Publications released in 2021

1. Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knecht RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults. *Hepatology*. 2021;73(3):968-82.
2. Angyal D, Bijvelds MJC, Bruno MJ, Peppelenbosch MP, de Jonge HR. Bicarbonate Transport in Cystic Fibrosis and Pancreatitis. *Cells*. 2021;11(1).
3. Arkenbosch JHC, Mak JWY, Ho JCL, Beelen EMJ, Erler NS, Hoentjen F, Bodelier AGL, Dijkstra G, Romberg-Camps M, de Boer NKH, Stassen LPS, van der Meulen AE, West R, van Ruler O, van der Woude CJ, Ng SC, de Vries AC. Indications, Postoperative Management, and Long-Term Prognosis of Crohn's Disease after Ileocecal Resection: A Multicentre Study Comparing the East and West. *Inflamm Bowel Dis*. 2021.
4. Ayada I, van Kleef LA, Alferink LJM, Li P, de Knecht RJ, Pan Q. Systematically Comparing Epidemiological and Clinical Features of Mafld and Nafld by Meta-Analysis: Focusing on the Non-Overlap Groups. *Liver Int*. 2021.
5. Bardi E, Mulder RL, van Dalen EC, Bhatt NS, Ruble KA, Burgis J, Castellino SM, Constine LS, den Hoed CM, Green DM, Koot BGP, Levitt G, Szonyi L, Wallace WH, Skinner R, Hudson MM, Kremer LCM, Effinger KE, Bresters D. Late Hepatic Toxicity Surveillance for Survivors of Childhood, Adolescent and Young Adult Cancer: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Cancer Treat Rev*. 2021;100:102296.
6. Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, de Vries AC, Dutch Initiative on Cs, Colitis. Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study. *Ann Surg*. 2021;273(3):557-63.
7. Beudeker BJB, Groothuismink ZMA, de Man RA, Witjes CDM, van der Eijk AA, Boonstra A, Sonneveld MJ. Hepatitis B Core-Related Antigen Levels Predict Recurrence-Free Survival in Patients with Hbv-Associated Early-Stage Hepatocellular Carcinoma: Results from a Dutch Long-Term Follow-up Study. *J Viral Hepat*. 2021;28(1):205-8.
8. Beudeker BJB, Janssen HLA, Boonstra A. Letter to the Editor: Entecavir Treatment Restores the Anti-Hbv Immune Response? *Hepatology*. 2021;74(4):2325-6.
9. Beudeker BJB, Voermans JJC, GeurtsvanKessel CH, de Knecht RJ, Kuhlemann T, Boonstra A, van der Eijk AA. Prevalence of Hepatitis Delta Virus among Chronic Hepatitis B Carriers in a Large Tertiary Center in the Netherlands. *J Clin Virol*. 2021;141:104870.
10. Beumer BR, Buettner S, Galjart B, van Vugt JLA, de Man RA, JNM IJ, Koerkamp BG. Systematic Review and Meta-Analysis of Validated Prognostic Models for Resected Hepatocellular Carcinoma Patients. *Eur J Surg Oncol*. 2021.
11. Beumer BR, de Wilde RF, Metselaar HJ, de Man RA, Polak WG, Ijzermans JNM. The Treatment Effect of Liver Transplantation Versus Liver Resection for Hcc: A Review and Future Perspectives. *Cancers (Basel)*. 2021;13(15).
12. Biewenga M, Verhelst X, Baven-Pronk M, Putter H, van den Berg AP, van Nieuwkerk K, van Buuren HR, Bouma G, de Boer YS, Simoen C, Colle I, Schouten J, Sermon F, van Steenkiste C, van Vlierberghe H, van der Meer AJ, Nevens F, van Hoek B, Dutch Autoimmune Hepatitis Study G. Development and Validation of a Prognostic Score for Long-Term Transplant-Free Survival in Autoimmune Hepatitis Type 1. *United European Gastroenterol J*. 2021;9(6):662-71.
13. Borren NZ, Paulides E, Frinack JL, Olson RN, Willrich MAV, van der Woude CJ, Ananthakrishnan AN. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with Ibd in Endoscopic Remission: A Multicenter Cohort Study. *Dig Dis Sci*. 2021;66(10):3548-54.
14. Bouzid R, de Beijer MTA, Luijten RJ, Bezstarosti K, Kessler AL, Bruno MJ, Peppelenbosch MP, Demmers JAA, Buschow SI. Empirical Evaluation of the Use of Computational Hla Binding as an Early Filter to the Mass Spectrometry-Based Epitope Discovery Workflow. *Cancers (Basel)*. 2021;13(10).
15. Boxhoorn L, Fritzsche JA, Fockens P, van Hooft JE, de Jonge PJF, Poley JW, Bruno MJ, Voermans RP. Clinical Outcome of Endoscopic Treatment for Symptomatic Sterile Walled-Off Necrosis. *Endoscopy*. 2021;53(2):136-44.

16. Boxhoorn L, Timmerhuis HC, Verdonk RC, Besselink MG, Bollen TL, Bruno MJ, Elmunzer BJ, Fockens P, Horvath KD, van Santvoort HC, Voermans RP, Dutch Pancreatitis Study G. Diagnosis and Treatment of Pancreatic Duct Disruption or Disconnection: An International Expert Survey and Case Vignette Study. *HPB (Oxford)*. 2021;23(8):1201-8.
17. Boxhoorn L, van Dijk SM, van Grinsven J, Verdonk RC, Boermeester MA, Bollen TL, Bouwense SAW, Bruno MJ, Cappendijk VC, Dejong CHC, van Duijvendijk P, van Eijck CHJ, Fockens P, Francken MFG, van Goor H, Hadithi M, Hallensleben ND, Haveman JW, Jacobs M, Jansen JM, Kop MPM, van Lienden KP, Manusama ER, Mieog JSD, Molenaar IQ, Nieuwenhuijs VB, Poen AC, Poley JW, van de Poll M, Quispel R, Romkens TEH, Schwartz MP, Seerden TC, Stommel MWJ, Straathof JWA, Timmerhuis HC, Venneman NG, Voermans RP, van de Vrie W, Wittteman BJ, Dijkgraaf MGW, van Santvoort HC, Besselink MG, Dutch Pancreatitis Study G. Immediate Versus Postponed Intervention for Infected Necrotizing Pancreatitis. *N Engl J Med*. 2021;385(15):1372-81.
18. Brakenhoff SM, de Man RA, Boonstra A, van Campenhout MJH, de Knegt RJ, van Bommel F, van der Eijk AA, Berg T, Hansen BE, Janssen HLA, Sonneveld MJ. Hepatitis B Virus Rna Decline without Concomitant Viral Antigen Decrease Is Associated with a Low Probability of Sustained Response and Hepatitis B Surface Antigen Loss. *Aliment Pharmacol Ther*. 2021;53(2):314-20.
19. Brakenhoff SM, de Man RA, de Knegt RJ, Janssen HLA, Sonneveld MJ. Editorial: Hbv Cure-the Quest for Biomarkers to Predict Off-Treatment Sustained Response. Authors' Reply. *Aliment Pharmacol Ther*. 2021;53(4):555-6.
20. Canena J, Lopes L, Fernandes J, Costa P, Arvanitakis M, Koch AD, Poley JW, Jimenez J, Dominguez-Munoz E, Familiari P, Bruno MJ, Dinis-Ribeiro M. Influence of a Novel Classification of the Papilla of Vater on the Outcome of Needle-Knife Fistulotomy for Biliary Cannulation. *BMC Gastroenterol*. 2021;21(1):147.
21. Choi HSJ, Sonneveld MJ, Farag MS, Brouwer WP, Brakenhoff SM, Hirode G, Gehring AJ, de Man RA, Hansen BE, Janssen HLA. Effects of on-Treatment Alt Flares on Serum Hbsag and Hbv Rna in Patients with Chronic Hbv Infection. *J Viral Hepat*. 2021;28(12):1729-37.
22. Choi HSJ, van Campenhout MJH, van Vuuren AJ, Krassenburg LAP, Sonneveld MJ, de Knegt RJ, Hansen BE, Janssen HLA. Ultra-Long-Term Follow-up of Interferon Alfa Treatment for Hbeag-Positive Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol*. 2021;19(9):1933-40 e1.
23. de Goede B, van Rooijen MMJ, van Kempen BJH, Polak WG, de Man RA, Taimr P, Lange JF, Metselaar HJ, Kazemier G. Conservative Treatment Versus Elective Repair of Umbilical Hernia in Patients with Liver Cirrhosis and Ascites: Results of a Randomized Controlled Trial (Crucial Trial). *Langenbecks Arch Surg*. 2021;406(1):219-25.
24. de Jong DM, Stassen PM, Poley JW, Fockens P, Timmer R, Voermans RP, Verdonk RC, Bruno MJ, de Jonge PJF. Clinical Outcome of Endoscopic Therapy in Patients with Symptomatic Pancreas Divisum: A Dutch Cohort Study. *Endosc Int Open*. 2021;9(7):E1164-E70.
25. de Klaver W, Wisse PHA, van Wifferen F, Bosch LJW, Jimenez CR, van der Hulst RWM, Fijneman RJA, Kuipers EJ, Greuter MJE, Carvalho B, Spaander MCW, Dekker E, Coupe VMH, de Wit M, Meijer GA. Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening : A Diagnostic Test Accuracy Study. *Ann Intern Med*. 2021;174(9):1224-31.
26. de Mattos AZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current Impact of Viral Hepatitis on Liver Cancer Development: The Challenge Remains. *World J Gastroenterol*. 2021;27(24):3556-67.
27. De Ridder F, Sonneveld MJ, Lenz O, Janssen HLA, Talloen W, Hansen BE. Mean Hbsag Decline at Week 24 of Peg-Ifn-Based Treatment Predicts Subsequent Rate of Hbsag Clearance - Suggesting a Valuable Endpoint for Early Development Hbv Trials. *J Viral Hepat*. 2021;28(11):1563-9.
28. de Veer RC, da Silva G, van Hooff MC, Harms MH, Metselaar HJ, Willemse J, Utomo E, van der Meer AJ. Measurement Properties of the Pbc-40 and Pbc-27: A Dutch Validation Study. *BMJ Open Gastroenterol*. 2021;8(1).
29. Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon C. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. *Cancers (Basel)*. 2021;13(7).
30. Eikenboom EL, van der Werf-t Lam AS, Rodriguez-Gironde M, Van Asperen CJ, Dinjens WNM, Hofstra RMW, Van Leerdam ME, Morreau H, Spaander MCW, Wagner A, Nielsen M. Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-Analysis of 58,580 Colorectal Carcinomas. *Clin Gastroenterol Hepatol*. 2021.

31. Eikenboom EL, van Doorn HC, Dinjens WNM, Dubbink HJ, Geurts-Giele WRR, Spaander MCW, Tops CMJ, Wagner A, Goverde A. Gynecological Surveillance and Surgery Outcomes in Dutch Lynch Syndrome Carriers. *Cancers (Basel)*. 2021;13(3).
32. Enigma European Network For The Investigation Of Gastrointestinal Mucosal A, Tran-Nguyen T, Fernandez-Esparrach G, Ash S, Balaguer F, Bird-Lieberman EL, Cordova H, Dzerve Z, Fassan M, Leja M, Lyutakov I, Middelburg T, Moreira L, Nakov R, Nieuwenburg SAV, O'Connor A, Realdon S, De Schepper H, Smet A, Spaander MCW, Tolmanis I, Urbonas T, Weigt J, Hold GL, Link A, Kupcinskas J, Alterations EENftloGM. Biopsy Sampling in Upper Gastrointestinal Endoscopy: A Survey from 10 Tertiary Referral Centres across Europe. *Dig Dis*. 2021;39(3):179-89.
33. Eyck BM, van der Wilk BJ, Noordman BJ, Wijnhoven BPL, Lagarde SM, Hartgrink HH, Coene P, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, van der Zaag ES, Spaander MCW, Valkema R, Lingsma HF, Steyerberg EW, van Lanschot JJB, group SA-s. Updated Protocol of the Sano Trial: A Stepped-Wedge Cluster Randomised Trial Comparing Surgery with Active Surveillance after Neoadjuvant Chemoradiotherapy for Oesophageal Cancer. *Trials*. 2021;22(1):345.
34. Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Ferenci P, Feld JJ, Berg T, Hansen BE, van Bommel F, Janssen HLA. Hepatitis B Virus Rna as Early Predictor for Response to Pegylated Interferon Alpha in Hbeag-Negative Chronic Hepatitis B. *Clin Infect Dis*. 2021;72(2):202-11.
35. Fritzsche JA, Fockens P, Barthet M, Bruno MJ, Carr-Locke DL, Costamagna G, Cote GA, Deprez PH, Giovannini M, Haber GB, Hawes RH, Hyun JJ, Itoi T, Iwasaki E, Kylanpaa L, Neuhaus H, Park JY, Reddy DN, Sakai A, Bourke MJ, Voermans RP. Expert Consensus on Endoscopic Papillectomy Using a Delphi Process. *Gastrointest Endosc*. 2021;94(4):760-73 e18.
36. Geerdes EE, Sideras K, Aziz MH, van Eijck CH, Bruno MJ, Sprengers D, Boor PPC, Kwekkeboom J. Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. *Front Oncol*. 2021;11:615691.
37. Goet JC, Murillo Perez CF, Harms MH, Floreani A, Cazzagon N, Bruns T, Prechter F, Dalekos GN, Verhelst X, Gatselis NK, Lindor KD, Lammers WJ, Gulamhusein A, Reig A, Carbone M, Nevens F, Hirschfield GM, van der Meer AJ, van Buuren HR, Hansen BE, Pares A, Group GPS. A Comparison of Prognostic Scores (Mayo, Uk-Pbc, and Globe) in Primary Biliary Cholangitis. *Am J Gastroenterol*. 2021;116(7):1514-22.
38. Goetgebuer RL, Kreijne JE, Aitken CA, Dijkstra G, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Pierik MJ, van Kemenade FJ, de Kok I, Siebers AG, Mannien J, van der Woude CJ, de Vries AC. Increased Risk of High-Grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-Controlled Cohort Study. *J Crohns Colitis*. 2021;15(9):1464-73.
39. Gorris M, Bruno MJ, Cahen DL, Fockens P, van Santvoort HC, van Hooft JE, Besselink MG. [Pancreatic Cystic Neoplasms: A Clinical Dilemma] Neoplastische Cysten Van Het Pancreas. *Ned Tijdschr Geneesk*. 2021;164.
40. Gotink AW, Peters Y, Bruno MJ, Siersema PD, Koch AD. Nonthermal Resection Device for Ablation of Barrett's Esophagus: A Feasibility and Safety Study. *Endoscopy*. 2021.
41. Gotink AW, van de Ven SEM, Ten Kate FJC, Nieboer D, Suzuki L, Weusten B, Brosens LAA, van Hillegersberg R, Alvarez Herrero L, Seldenrijk CA, Alkhalaf A, Moll FCP, Schoon EJ, van Lijnschoten I, Tang TJ, van der Valk H, Nagengast WB, Kats-Ugurlu G, Plukker JTM, Houben M, van der Laan JS, Pouw RE, Bergman J, Meijer SL, van Berge Henegouwen MI, Wijnhoven BPL, de Jonge PJF, Doukas M, Bruno MJ, Biermann K, Koch AD. Individual Risk Calculator to Predict Lymph Node Metastases in Patients with Submucosal (T1b) Esophageal Adenocarcinoma: A Multicenter Cohort Study. *Endoscopy*. 2021.
42. Hallensleben ND, Timmerhuis HC, Hollemans RA, Pocornie S, van Grinsven J, van Brunschot S, Bakker OJ, van der Sluijs R, Schwartz MP, van Duijvendijk P, Romkens T, Stommel MWJ, Verdonk RC, Besselink MG, Bouwense SAW, Bollen TL, van Santvoort HC, Bruno MJ, Dutch Pancreatitis Study G. Optimal Timing of Cholecystectomy after Necrotising Biliary Pancreatitis. *Gut*. 2021.
43. Hubers LM, Schuurman AR, Buijs J, Mostafavi N, Bruno MJ, Vermeulen RCH, Huss A, van Buuren HR, Beuers U. Blue-Collar Work Is a Risk Factor for Developing Igg4-Related Disease of the Biliary Tract and Pancreas. *JHEP Rep*. 2021;3(6):100385.



44. Isfordink CJ, Maan R, de Man RA, van Erpecum KJ, van der Meer AJ. Should We Continue Surveillance for Hepatocellular Carcinoma and Gastroesophageal Varices in Patients with Cirrhosis and Cured Hcv Infection? *Eur J Intern Med.* 2021;94:6-14.
45. Janmaat VT, Nesteruk K, Spaander MCW, Verhaar AP, Yu B, Silva RA, Phillips WA, Magierowski M, van de Winkel A, Stadler HS, Sandoval-Guzman T, van der Laan LJW, Kuipers EJ, Smits R, Bruno MJ, Fuhler GM, Clemons NJ, Peppelenbosch MP. Hoxa13 in Etiology and Oncogenic Potential of Barrett's Esophagus. *Nat Commun.* 2021;12(1):3354.
46. Kamp E, Dinjens WNM, Doukas M, Bruno MJ, de Jonge PJF, Peppelenbosch MP, de Vries AC. Optimal Tissue Sampling During Ercp and Emerging Molecular Techniques for the Differentiation of Benign and Malignant Biliary Strictures. *Therap Adv Gastroenterol.* 2021;14:17562848211002023.
47. Kamp E, Peppelenbosch MP, Doukas M, Verheij J, Ponsioen CY, van Marion R, Bruno MJ, Koerkamp BG, Dinjens WNM, de Vries AC. Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity. *Clin Transl Gastroenterol.* 2021;12(10):e00410.
48. Kanis SL, Modderman S, Escher JC, Erler N, Beukers R, de Boer N, Bodelier A, Depla A, Dijkstra G, van Dijk ARM, Gilissen L, Hoentjen F, Jansen JM, Kuyvenhoven J, Mahmmud N, Mallant-Hent RC, van der Meulen-de Jong AE, Noruzi A, Oldenburg B, Oostenbrug LE, Ter Borg PCJ, Pierik M, Romberg-Camps M, Thijs W, West R, de Lima A, van der Woude CJ, Initiative on C, Colitis. Health Outcomes of 1000 Children Born to Mothers with Inflammatory Bowel Disease in Their First 5 Years of Life. *Gut.* 2021;70(7):1266-74.
49. Karabegovic I, Portilla-Fernandez E, Li Y, Ma J, Maas SCE, Sun D, Hu EA, Kuhnel B, Zhang Y, Ambatipudi S, Fiorito G, Huang J, Castillo-Fernandez JE, Wiggins KL, de Klein N, Grioni S, Swenson BR, Polidoro S, Treur JL, Cuenin C, Tsai PC, Costeira R, Chajes V, Braun K, Verweij N, Kretschmer A, Franke L, van Meurs JBJ, Uitterlinden AG, de Knecht RJ, Ikram MA, Dehghan A, Peters A, Schottker B, Gharib SA, Sotoodehnia N, Bell JT, Elliott P, Vineis P, Relton C, Herceg Z, Brenner H, Waldenberger M, Rebholz CM, Voortman T, Pan Q, Fornage M, Levy D, Kayser M, Ghanbari M. Epigenome-Wide Association Meta-Analysis of DNA Methylation with Coffee and Tea Consumption. *Nat Commun.* 2021;12(1):2830.
50. Kempeneers MA, Issa Y, Ahmed Ali U, Bruno MJ, van Geenen EJM, van Hooft JE, Romkens TEH, Siersema PD, Spanier BWM, Yahya I, DeVries JH, Besselink MG, van Santvoort HC, Boermeester MA, Dutch Pancreatitis Study G. A Classification Algorithm for Types of Diabetes in Chronic Pancreatitis Using Epidemiological Characteristics: Outcome of a Longitudinal Cohort Study. *Pancreas.* 2021;50(10):1407-14.
51. Kirkegaard-Klitbo DM, Bendtsen F, Lundgren J, de Knecht RJ, Kofoed KF, Nielsen SD, Benfield T. Increased Prevalence of Liver Fibrosis in People Living with Human Immunodeficiency Virus without Viral Hepatitis Compared to Population Controls. *J Infect Dis.* 2021;224(3):443-52.
52. Koopmann BDM, Harinck F, Kroep S, Konings I, Naber SK, Lansdorp-Vogelaar I, Fockens P, van Hooft JE, Cahen DL, van Ballegooijen M, Bruno MJ, de Kok I. Identifying Key Factors for the Effectiveness of Pancreatic Cancer Screening: A Model-Based Analysis. *Int J Cancer.* 2021;149(2):337-46.
53. Kooyker AI, Toes-Zoutendijk E, Opstal-van Winden AWJ, Buskermolen M, van Vuuren HJ, Kuipers EJ, van Kemenade FJ, Ramakers C, Dekker E, Nagtegaal ID, de Koning HJ, Spaander MCW, Lansdorp-Vogelaar I, van Leerdam ME. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. *Clin Gastroenterol Hepatol.* 2021;19(7):1418-25.
54. Kortlever TL, de Jonge L, Wisse PHA, Seriese I, Otto-Terlouw P, van Leerdam ME, Spaander MCW, Dekker E, Lansdorp-Vogelaar I. The National Fit-Based Colorectal Cancer Screening Program in the Netherlands During the Covid-19 Pandemic. *Prev Med.* 2021;151:106643.
55. Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, de Knecht RJ, Hansen BE, Janssen HLA, de Man RA, Feld JJ, van der Meer AJ. Clinical Outcomes Following Daa Therapy in Patients with Hcv-Related Cirrhosis Depend on Disease Severity. *J Hepatol.* 2021;74(5):1053-63.
56. Kuscuoglu D, Bewersdorf L, Wenzel K, Gross A, Kobazi Ensari G, Luo Y, Kilic K, Hittatiya K, Golob-Schwarzl N, Leube RE, Preisinger C, George J, Metwally M, Eslam M, Lampertico P, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML, Loglio A, Sutton A, Nahon P, Schaefer B, Zoller H, Aigner E, Trautwein C, Haybaeck J, Strnad P. Dual Proteotoxic Stress Accelerates Liver Injury Via Activation of P62-Nrf2. *J Pathol.* 2021;254(1):80-91.

57. Kuttner-Magalhaes R, Pimentel-Nunes P, Araujo-Martins M, Libanio D, Borges-Canha M, Marcos-Pinto R, Koch AD, Dinis-Ribeiro M. Endoscopic Submucosal Dissection (Esd): How Do Western Endoscopists Value Animal Models? *Scand J Gastroenterol.* 2021;56(4):492-7.
58. Kwakman JA, Erler NS, Vos MC, Bruno MJ. Risk Evaluation of Duodenoscopy-Associated Infections in the Netherlands Calls for a Heightened Awareness of Device-Related Infections: A Systematic Review. *Endoscopy.* 2021.
59. Kwakman JA, Rauwers AW, Klaassen CHW, Bruno MJ, Vos MC. Investigation of Possible Transmission of a Susceptible Microorganism through a Contaminated Duodenoscopy; a Case Report. *Antimicrob Resist Infect Control.* 2021;10(1):127.
60. Lantinga MA, Theunissen F, Ter Borg PCJ, Bruno MJ, Ouwendijk RJT, Siersema PD, Trans ITfsg. Correction: Impact of the Covid-19 Pandemic on Gastrointestinal Endoscopy in the Netherlands: Analysis of a Prospective Endoscopy Database. *Endoscopy.* 2021;53(2):C11.
61. Lantinga MA, Theunissen F, Ter Borg PCJ, Bruno MJ, Ouwendijk RJT, Siersema PD, Trans ITfsg. Impact of the Covid-19 Pandemic on Gastrointestinal Endoscopy in the Netherlands: Analysis of a Prospective Endoscopy Database. *Endoscopy.* 2021;53(2):166-70.
62. Latenstein AEJ, Mackay TM, van Huijgevoort NCM, Bonsing BA, Bosscha K, Hol L, Bruno MJ, van Coolsen MME, Festen S, van Geenen E, Groot Koerkamp B, Hemmink GJM, de Hingh I, Kazemier G, Lubbinge H, de Meijer VE, Molenaar IQ, Quispel R, van Santvoort HC, Seerden TCJ, Stommel MWJ, Venneman NG, Verdonk RC, Besselink MG, van Hooft JE, Dutch Pancreatic Cancer G. Nationwide Practice and Outcomes of Endoscopic Biliary Drainage in Resectable Pancreatic Head and Periampullary Cancer. *HPB (Oxford).* 2021;23(2):270-8.
63. Li Y, Miao Z, Li P, Zhang R, Kainov DE, Ma Z, de Man RA, Peppelenbosch MP, Pan Q. Ivermectin Effectively Inhibits Hepatitis E Virus Replication, Requiring the Host Nuclear Transport Protein Importin Alpha1. *Arch Virol.* 2021;166(7):2005-10.
64. Libanio D, Rodrigues JR, Bento MJ, Ebigbo A, Messman H, Verhoeven RHA, Van Damme N, Bisschops R, Spaander MCW, Dinis-Ribeiro M. Gastric Cancer Incidence and Mortality Trends 2007-2016 in Three European Countries. *Endoscopy.* 2021.
65. Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knecht RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. *Clin Gastroenterol Hepatol.* 2021.
66. Liu WY, Zhang X, Li G, Tang LJ, Zhu PW, Rios RS, Zheng KI, Ma HL, Wang XD, Pan Q, de Knecht RJ, Valenti L, Ghanbari M, Zheng MH. Protective Association of Klotho Rs495392 Gene Polymorphism against Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease Patients. *Clin Mol Hepatol.* 2021.
67. Maan R, Darwish Murad S, van der Meer AJ. Letter to the Editor: Effects of Early Placement of Transjugular Portosystemic Shunts in Patients with High-Risk Acute Variceal Bleeding: A Meta-Analysis of Individual Patient Data. *Gastroenterology.* 2021;161(1):371-2.
68. Maan R, Sonneveld MJ. Editorial: Stratifying Risk of Adverse Outcomes in Cirrhosis: The Hepquant Shunt Test. *Aliment Pharmacol Ther.* 2021;53(8):939-40.
69. Maan R, van der Meer AJ. Hepatocellular Carcinoma (Hcc) Risk Stratification after Virological Cure for Hepatitis C Virus (Hcv)-Induced Cirrhosis: Time to Refine Predictive Models. *Hepatobiliary Surg Nutr.* 2021;10(3):385-7.
70. Marta K, Gede N, Szakacs Z, Solymar M, Hegyi PJ, Tel B, Eross B, Vincze A, Arvanitakis M, Boskoski I, Bruno MJ, Hegyi P. Combined Use of Indomethacin and Hydration Is the Best Conservative Approach for Post-Ercp Pancreatitis Prevention: A Network Meta-Analysis. *Pancreatology.* 2021;21(7):1247-55.
71. Mattos AZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune Aspects of Hepatocellular Carcinoma: From Immune Markers for Early Detection to Immunotherapy. *World J Gastrointest Oncol.* 2021;13(9):1132-43.
72. Mommersteeg MC, Nieuwenburg SAV, den Hollander WJ, Holster L, den Hoed CM, Capelle LG, Tang TJ, Anten MP, Prytz-Berset I, Witteman EM, Ter Borg F, Burger JPW, Doukas M, Bruno MJ, Peppelenbosch MP, Fuhler GM, Kuipers EJ, Spaander MCW. Accuracy of Upper Endoscopies with Random Biopsies to Identify Patients with Gastric Premalignant Lesions Who Can Safely Be Exempt from Surveillance. *Gastric Cancer.* 2021;24(3):680-90.

73. Mulder MB, de Man RA, Kamar N, Durmaz G, de Bruijne J, Vanwollegheem T, Izopet J, Gandia P, van der Eijk AA, van Gelder T, Hesselink DA, de Winter BCM. Determining the Therapeutic Range for Ribavirin in Transplant Recipients with Chronic Hepatitis E Virus Infection. *J Viral Hepat.* 2021;28(2):431-5.
74. Nass KJ, van der Schaar PJ, van der Vlugt M, Ledebouer M, van Esch AAJ, van der Beek S, Lacle MM, van Leerdam ME, Ouwendijk RJT, Spaander MCW, Wouters M, Fockens P, Dekker E. Continuous Monitoring of Colonoscopy Performance in the Netherlands: First Results of a Nationwide Registry. *Endoscopy.* 2021.
75. Nieuwenburg SAV, Mommersteeg MC, Eikenboom EL, Yu B, den Hollander WJ, Holster IL, den Hoed CM, Capelle LG, Tang TJ, Anten MP, Prytz-Berset I, Witteman EM, Ter Borg F, Burger JPW, Bruno MJ, Fuhler GM, Peppelenbosch MP, Doukas M, Kuipers EJ, Spaander MCW. Factors Associated with the Progression of Gastric Intestinal Metaplasia: A Multicenter, Prospective Cohort Study. *Endosc Int Open.* 2021;9(3):E297-E305.
76. Nieuwenburg SAV, Mommersteeg MC, Wolters LMM, van Vuuren AJ, Erler N, Peppelenbosch MP, Fuhler GM, Bruno MJ, Kuipers EJ, Spaander MCW. Accuracy of H. Pylori Fecal Antigen Test Using Fecal Immunochemical Test (Fit). *Gastric Cancer.* 2021.
77. Noordam L, Ge Z, Ozturk H, Doukas M, Mancham S, Boor PPC, Campos Carrascosa L, Zhou G, van den Bosch TPP, Pan Q, JNM IJ, Bruno MJ, Sprengers D, Kwekkeboom J. Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. *Cancers (Basel).* 2021;13(10).
78. Omidvari AH, Roumans CAM, Naber SK, Kroep S, Wijnhoven BPL, van der Gaast A, de Jonge PJ, Spaander MCW, Lansdorp-Vogelaar I. Correction To: The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management. *Am J Gastroenterol.* 2021;116(2):435-9.
79. Overbeek KA, Goggins MG, Dbouk M, Levink IJM, Koopmann BDM, Chuidian M, Konings I, Paiella S, Earl J, Fockens P, Gress TM, Ausems M, Poley JW, Thosani NC, Half E, Lachter J, Stoffel EM, Kwon RS, Stoita A, Kastrinos F, Lucas AL, Syngal S, Brand RE, Chak A, Carrato A, Vleggaar FP, Bartsch DK, van Hooft JE, Cahen DL, Canto MI, Bruno MJ, International Cancer of the Pancreas Screening C. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. *Gastroenterology.* 2021.
80. Overbeek KA, Levink IJM, Koopmann BDM, Harinck F, Konings I, Ausems M, Wagner A, Fockens P, van Eijck CH, Groot Koerkamp B, Busch ORC, Besselink MG, Bastiaansen BAJ, van Driel L, Erler NS, Vleggaar FP, Poley JW, Cahen DL, van Hooft JE, Bruno MJ, Dutch Familial Pancreatic Cancer Surveillance Study G. Long-Term Yield of Pancreatic Cancer Surveillance in High-Risk Individuals. *Gut.* 2021.
81. Overbeek KA, Rodriguez-Gironde MD, Wagner A, van der Stoep N, van den Akker PC, Oosterwijk JC, van Os TA, van der Kolk LE, Vasen HFA, Hes FJ, Cahen DL, Bruno MJ, Potjer TP. Genotype-Phenotype Correlations for Pancreatic Cancer Risk in Dutch Melanoma Families with Pathogenic Cdkn2a Variants. *J Med Genet.* 2021;58(4):264-9.
82. Overwater A, van Munster SN, Offerhaus GJA, Seldenrijk CA, Raicu GM, Koch AD, Bergman J, Pouw RE, Brosens LAA, Jansen M, Weusten B. Extension of Early Esophageal Squamous Cell Neoplasia into Ducts and Submucosal Glands and the Role of Endoscopic Ablation Therapy. *Gastrointest Endosc.* 2021;94(4):832-42 e2.
83. Paulides E, Boukema I, van der Woude CJ, de Boer NKH. The Effect of Psychotherapy on Quality of Life in Ibd Patients: A Systematic Review. *Inflamm Bowel Dis.* 2021;27(5):711-24.
84. Paulides E, Pasma A, Erler NS, van Eijk RLA, de Vries AC, van der Woude CJ. Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease. *Dig Dis Sci.* 2021.
85. Pauwels RWM, Proietti E, van der Woude CJ, Oudijk L, Crombag MBS, Peppelenbosch MP, Grohmann U, Fuhler GM, de Vries AC. Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2021;27(11):1813-20.
86. Pauwels RWM, van der Woude CJ, Nieboer D, Steyerberg EW, Casanova MJ, Gisbert JP, Kennedy NA, Lees CW, Louis E, Molnar T, Szanto K, Leo E, Bots S, Downey R, Lukas M, Lin WC, Amiot A, Lu C, Roblin X, Farkas K, Seidelin JB, Duijvestein M, D'Haens GR, de Vries AC, Group CS. Prediction of Relapse after Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-Analysis of 1317 Patients from 14 Studies. *Clin Gastroenterol Hepatol.* 2021.

87. Pazoki R, Vujkovic M, Elliott J, Evangelou E, Gill D, Ghanbari M, van der Most PJ, Pinto RC, Wielscher M, Farlik M, Zuber V, de Knecht RJ, Snieder H, Uitterlinden AG, Lifelines Cohort S, Lynch JA, Jiang X, Said S, Kaplan DE, Lee KM, Serper M, Carr RM, Tsao PS, Atkinson SR, Dehghan A, Tzoulaki I, Ikram MA, Herzig KH, Jarvelin MR, Alizadeh BZ, O'Donnell CJ, Saleheen D, Voight BF, Chang KM, Thursz MR, Elliott P, Program VAMV. Genetic Analysis in European Ancestry Individuals Identifies 517 Loci Associated with Liver Enzymes. *Nat Commun.* 2021;12(1):2579.
88. Pouw RE, Barret M, Biermann K, Bisschops R, Czako L, Gecse KB, de Hertogh G, Hucl T, Iacucci M, Jansen M, Rutter M, Savarino E, Spaander MCW, Schmidt PT, Vieth M, Dinis-Ribeiro M, van Hooft JE. Endoscopic Tissue Sampling - Part 1: Upper Gastrointestinal and Hepatopancreatobiliary Tracts. *European Society of Gastrointestinal Endoscopy (Esge) Guideline. Endoscopy.* 2021;53(11):1174-88.
89. Pouw RE, Bisschops R, Gecse KB, de Hertogh G, Iacucci M, Rutter M, Barret M, Biermann K, Czako L, Hucl T, Jansen M, Savarino E, Spaander MCW, Schmidt PT, Dinis-Ribeiro M, Vieth M, van Hooft JE. Endoscopic Tissue Sampling - Part 2: Lower Gastrointestinal Tract. *European Society of Gastrointestinal Endoscopy (Esge) Guideline. Endoscopy.* 2021;53(12):1261-73.
90. Quispel R, Schutz HM, Hallensleben ND, Bhalla A, Timmer R, van Hooft JE, Venneman NG, Erler NS, Veldt BJ, van Driel L, Bruno MJ. Do Endosonographers Agree on the Presence of Bile Duct Sludge and the Subsequent Need for Intervention? *Endosc Int Open.* 2021;9(6):E911-E7.
91. Ramchandani M, Lakhtakia S, Costamagna G, Tringali A, Puspoek A, Tribl B, Dolak W, Deviere J, Arvanitakis M, van der Merwe S, Laleman W, Ponchon T, Lepilliez V, Gabbriellini A, Bernardoni L, Bruno MJ, Poley JW, Arnelo U, Lau J, Roy A, Bourke M, Kaffes A, Neuhaus H, Peetermans J, Rousseau M, Reddy DN. Fully Covered Self-Expanding Metal Stent Vs Multiple Plastic Stents to Treat Benign Biliary Strictures Secondary to Chronic Pancreatitis: A Multicenter Randomized Trial. *Gastroenterology.* 2021;161(1):185-95.
92. Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. *Cancers (Basel).* 2021;13(19).
93. Rico Montanari N, Ramirez R, Van Buuren N, van den Bosch TPP, Doukas M, Debes JD, Feierbach B, Boonstra A. Transcriptomic Analysis of Livers of Inactive Carrier Hbv Patients with Differential Hbsag. *J Infect Dis.* 2021.
94. Roos FJM, Wu H, Willemse J, Lieshout R, Albarinos LAM, Kan YY, Poley JW, Bruno MJ, de Jonge J, Bartfai R, Marks H, JNM IJ, Verstegen MMA, van der Laan LJW. Cholangiocyte Organoids from Human Bile Retain a Local Phenotype and Can Repopulate Bile Ducts in Vitro. *Clin Transl Med.* 2021;11(12):e566.
95. Sari G, Mulders CE, Zhu J, van Oord GW, Feng Z, Kreeft-Voermans JJC, Boonstra A, Vanwollegghem T. Treatment Induced Clearance of Hepatitis E Viruses by Interferon-Lambda in Liver-Humanized Mice. *Liver Int.* 2021;41(12):2866-73.
96. Sari G, Zhu J, Ambardekar C, Yin X, Boonstra A, Feng Z, Vanwollegghem T. The Viral Orf3 Protein Is Required for Hepatitis E Virus Apical Release and Efficient Growth in Polarized Hepatocytes and Humanized Mice. *J Virol.* 2021;95(23):e0058521.
97. Schouten WR, Arkenbosch JHC, van der Woude CJ, de Vries AC, Stevens HP, Fuhler GM, Dwarkasing RS, van Ruler O, de Graaf EJR. Efficacy and Safety of Autologous Adipose-Derived Stromal Vascular Fraction Enriched with Platelet-Rich Plasma in Flap Repair of Transsphincteric Cryptoglandular Fistulas. *Tech Coloproctol.* 2021;25(12):1301-9.
98. Sleutjes JAM, de Vries AC, van der Woude CJ, Roeters van Lennep JE. Lipid Profiles in Patients with Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. *Inflamm Bowel Dis.* 2021;27(3):e25.
99. Sleutjes JAM, Roeters van Lennep JE, Boersma E, Menchen LA, Laudes M, Farkas K, Molnar T, Kennedy NA, Pierik MJ, van der Woude CJ, de Vries AC. Systematic Review with Meta-Analysis: Effect of Inflammatory Bowel Disease Therapy on Lipid Levels. *Aliment Pharmacol Ther.* 2021;54(8):999-1012.
100. Sleutjes JAM, van Lennep JER, van der Woude CJ, de Vries AC. Thromboembolic and Atherosclerotic Cardiovascular Events in Inflammatory Bowel Disease: Epidemiology, Pathogenesis and Clinical Management. *Therap Adv Gastroenterol.* 2021;14:17562848211032126.
101. Slivka A, Ross AS, Sejpal DV, Petersen BT, Bruno MJ, Pleskow DK, Muthusamy VR, Chennat JS, Krishnamoorthi R, Lee C, Martin JA, Poley JW, Cohen JM, Thaker AM, Peetermans JA, Rousseau MJ, Tirrell GP, Kozarek RA, Group ES-

- uDS. Single-Use Duodenoscope for Ercp Performed by Endoscopists with a Range of Experience in Procedures of Variable Complexity. *Gastrointest Endosc.* 2021;94(6):1046-55.
102. Sonneveld MJ, Brouwer WP, de Man RA, Janssen HLA, Group S-BS. Letter: Rates and Determinants of Significant Liver Inflammation in Chronic Hepatitis B Virus-Infected Patients with Low Alt Levels in the Absence of Significant Fibrosis-Authors' Reply. *Aliment Pharmacol Ther.* 2021;53(1):215-6.
  103. Sonneveld MJ, Gehring AJ, Janssen HLA. Nucleic Acid Polymer Therapy for Hepatitis B Virus: Strong Hepatitis B Surface Antigen Decline but Many Unanswered Questions. *Gastroenterology.* 2021;160(3):966-7.
  104. Sonneveld MJ, Maasoumy B. Prevalence of Hepatitis D Virus Co-Infection in Austria - Finding the Needle in the Haystack. *United European Gastroenterol J.* 2021;9(10):1105-6. Sonneveld MJ, Maasoumy B. Reply. *Clin Gastroenterol Hepatol.* 2021.
  105. Sonneveld MJ, Veldhuijzen IK, van de Laar TJW, Op de Coul ELM, van der Meer AJ. Decrease in Viral Hepatitis Diagnoses During the Covid-19 Pandemic in the Netherlands. *J Hepatol.* 2021.Spaander MCW, Kuipers EJ. Editorial: Machine Learning Models for Gastric Cancer Risk Prediction. *Aliment Pharmacol Ther.* 2021;53(8):943-4.
  106. Spaander MCW, van der Bogt RD, Baron TH, Albers D, Blero D, de Ceglie A, Conio M, Czako L, Everett S, Garcia-Pagan JC, Gines A, Jovani M, Repici A, Rodrigues-Pinto E, Siersema PD, Fuccio L, van Hooft JE. Esophageal Stenting for Benign and Malignant Disease: European Society of Gastrointestinal Endoscopy (Esge) Guideline - Update 2021. *Endoscopy.* 2021;53(7):751-62.
  107. Sperna Weiland CJ, Busch CBE, Bhalla A, Bruno MJ, Fockens P, van Hooft JE, Poen AC, Timmerhuis HC, Umans DS, Venneman NG, Verdonk RC, Drenth JPH, de Wijkerslooth TR, van Geenen EJM, Dutch Pancreatitis Study G. Performance of Diagnostic Tools for Acute Cholangitis in Patients with Suspected Biliary Obstruction. *J Hepatobiliary Pancreat Sci.* 2021.
  108. Sperna Weiland CJ, Engels MML, Poen AC, Bhalla A, Venneman NG, van Hooft JE, Bruno MJ, Verdonk RC, Fockens P, Drenth JPH, van Geenen EJM, Dutch Pancreatitis Study G. Increased Use of Prophylactic Measures in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. *Dig Dis Sci.* 2021;66(12):4457-66.
  109. Sperna Weiland CJ, Smeets X, Kievit W, Verdonk RC, Poen AC, Bhalla A, Venneman NG, Witteman BJM, da Costa DW, van Eijck BC, Schwartz MP, Romkens TEH, Vrolijk JM, Hadithi M, Voorburg A, Baak LC, Thijs WJ, van Wanrooij RL, Tan A, Seerden TCJ, Keulemans YCA, de Wijkerslooth TR, van de Vrie W, van der Schaar P, van Dijk SM, Hallensleben NDL, Sperna Weiland RL, Timmerhuis HC, Umans DS, van Hooft JE, van Goor H, van Santvoort HC, Besselink MG, Bruno MJ, Fockens P, Drenth JPH, van Geenen EJM, Dutch Pancreatitis Study G. Aggressive Fluid Hydration Plus Non-Steroidal Anti-Inflammatory Drugs Versus Non-Steroidal Anti-Inflammatory Drugs Alone for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis (Fluyt): A Multicentre, Open-Label, Randomised, Controlled Trial. *Lancet Gastroenterol Hepatol.* 2021;6(5):350-8.
  110. Stassen PMC, de Jong DM, Poley JW, Bruno MJ, de Jonge PJF. Prevalence of and Risk Factors for Stent Migration-Induced Duodenal Perforation. *Endosc Int Open.* 2021;9(3):E461-E9.
  111. Stassen PMC, de Jonge PJF, Bruno MJ, Koch AD, Trindade AJ, Benias PC, Sejjal DV, Siddiqui UD, Chapman CG, Villa E, Tharian B, Inamdar S, Hwang JH, Barakat MT, Andalib I, Gaidhane M, Sarkar A, Shahid H, Tyberg A, Binmoeller K, Watson RR, Nett A, Schlag C, Abdelhafez M, Friedrich-Rust M, Schlachterman A, Chiang AL, Loren D, Kowalski T, Kahaleh M. Safety and Efficacy of a Novel Resection System for Direct Endoscopic Necrosectomy of Walled-Off Pancreas Necrosis: A Prospective, International, Multicenter Trial. *Gastrointest Endosc.* 2021.
  112. Stassen PMC, de Jonge PJF, Webster GJM, Ellrichmann M, Dormann AJ, Udd M, Bruno MJ, Cennamo V, European Cholangioscopy G, and the German Spyglass User G. Clinical Practice Patterns in Indirect Peroral Cholangiopancreatography: Outcome of a European Survey. *Endosc Int Open.* 2021;9(11):E1704-E11.
  113. Stassen PMC, Goodchild G, de Jonge PJF, Erler NS, Anderloni A, Cennamo V, Church NI, Fernandez-Urien Sainz I, Huggett MT, James MW, Joshi D, Kylanpaa L, Laleman W, Nayar MK, Oppong KW, Poley JW, Potts JR, Repici A, Udd M, Vila JJ, Wong T, Bruno MJ, Webster GJM, European Cholangioscopy G. Diagnostic Accuracy and Interobserver Agreement of Digital Single-Operator Cholangioscopy for Indeterminate Biliary Strictures. *Gastrointest Endosc.* 2021;94(6):1059-68.
  114. Straatmijer T, Biemans VBC, Hoentjen F, de Boer NKH, Bodelier AGL, Dijkstra G, van Dop WA, Haans JJJ, Jansen JM, Maljaars PWJ, van der Marel S, Oldenburg B, Ponsioen CY, Visschedijk MC, de Vries AC, West RL, van der Woude

- CJ, Pierik M, Duijvestein M, van der Meulen-de Jong AE. Ustekinumab B for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (Icc) Registry, a Nationwide Prospective Observational Cohort Study. *J Crohns Colitis*. 2021;15(11):1920-30.
115. Strijker M, van der Sijde F, Suker M, Boermeester MA, Bonsing BA, Bruno MJ, Busch OR, Doukas M, van Eijck CH, Gerritsen A, Groot Koerkamp B, Haj Mohammad N, van Hilst J, de Hingh IH, van Hooft JE, Luyer MD, Quintus Molenaar I, Verheij J, Waasdorp C, Wilmink JW, Besselink MG, van Laarhoven HW, Bijlsma MF, Dutch Pancreatic Cancer G. Preoperative Serum Adam12 Levels as a Stromal Marker for Overall Survival and Benefit of Adjuvant Therapy in Patients with Resected Pancreatic and Periampullary Cancer. *HPB (Oxford)*. 2021;23(12):1886-96.
116. Ten Bokkel Huinink S, Biemans V, Duijvestein M, Pierik M, Hoentjen F, West RL, van der Woude CJ, de Vries AC. Re-Induction with Intravenous Ustekinumab after Secondary Loss of Response Is a Valid Optimization Strategy in Crohn's Disease. *Eur J Gastroenterol Hepatol*. 2021.
117. Ten Kate CA, Tambucci R, Vlot J, Spaander MCW, Gottrand F, Wijnen RMH, Dall'Oglio L. An International Survey on Anastomotic Stricture Management after Esophageal Atresia Repair: Considerations and Advisory Statements. *Surg Endosc*. 2021;35(7):3653-61.
118. Ten Kate CA, Vlot J, Kamphuis LS, H IJ, Spaander MCW. [Long-Term Consequences of Esophageal Atresia; Esophageal and Lung Abnormalities in Adulthood] Langetermijnevolgen Van Slokdarmatresie. *Ned Tijdschr Geneeskd*. 2021;165.
119. Terlouw LG, van Noord D, van Walsum T, Bruno MJ, Moelker A. Mesenteric Artery Calcium Scoring: A Potential Screening Method for Chronic Mesenteric Ischemia. *Eur Radiol*. 2021;31(6):4212-20.
120. Terlouw LG, van Noord D, van Walsum T, van Dijk LJD, Moelker A, Bruno MJ. Early Risk Stratification of Patients with Suspected Chronic Mesenteric Ischaemia Using a Symptom and Mesenteric Artery Calcium Score Based Score Chart. *United European Gastroenterol J*. 2021;9(5):626-34.
121. Theunissen F, Lantinga MA, Borg P, Ouwendijk RJT, Bruno MJ, Siersema PD, Trans ITFSG. The Yield of Upper Gastrointestinal Endoscopy in Patients Below 60 Years and without Alarm Symptoms Presenting with Dyspepsia. *Scand J Gastroenterol*. 2021;56(6):740-6.
122. Theunissen F, van der Wiel SE, Ter Borg PCJ, Koch AD, Ouwendijk RJT, Slangen RME, Siersema PD, Bruno MJ, Trans ITfsg. Implementation of Mandatory Ercp Registration in the Netherlands and Compliance with European Society of Gastrointestinal Endoscopy Performance Measures: A Multicenter Database Study. *Endoscopy*. 2021.
123. Timmerhuis HC, van Dijk SM, Verdonk RC, Bollen TL, Bruno MJ, Fockens P, van Hooft JE, Voermans RP, Besselink MG, van Santvoort HC, Dutch Pancreatitis Study G. Various Modalities Accurate in Diagnosing a Disrupted or Disconnected Pancreatic Duct in Acute Pancreatitis: A Systematic Review. *Dig Dis Sci*. 2021;66(5):1415-24.
124. Tokat M, van Tilburg L, Koch AD, Spaander MCW. Artificial Intelligence in Upper Gastrointestinal Endoscopy. *Dig Dis*. 2021.
125. Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic Drug Monitoring of Immunosuppressive Drugs in Hepatology and Gastroenterology. *Best Pract Res Clin Gastroenterol*. 2021;54-55:101756.
126. Valkema MJ, van der Wilk BJ, Eyck BM, Wijnhoven BPL, Spaander MCW, Doukas M, Lagarde SM, Schreurs WMJ, Roef MJ, van Lanschot JJB, Valkema R. Surveillance of Clinically Complete Responders Using Serial (18)F-Fdg Pet/Ct Scans in Patients with Esophageal Cancer after Neoadjuvant Chemoradiotherapy. *J Nucl Med*. 2021;62(4):486-92.
127. van de Ven SEM, de Graaf W, Bugter O, Spaander MCW, Nikkessen S, de Jonge PJF, Hardillo JA, Sewnaik A, Monserez DA, Mast H, Keereweer S, Bruno MJ, Baatenburg de Jong RJ, Koch AD. Screening for Synchronous Esophageal Second Primary Tumors in Patients with Head and Neck Cancer. *Dis Esophagus*. 2021;34(10).
128. van de Ven SEM, Falger JM, Verhoeven RHA, Baatenburg de Jong RJ, Spaander MCW, Bruno MJ, Koch AD. Increased Risk of Second Primary Tumours in Patients with Oesophageal Squamous Cell Carcinoma: A Nationwide Study in a Western Population. *United European Gastroenterol J*. 2021;9(4):497-506.
129. van de Ven SEM, Spaander MCW, Pouw RE, Tang TJ, Houben M, Schoon EJ, de Jonge PJF, Bruno MJ, Koch AD. Favorable Effect of Endoscopic Reassessment of Clinically Staged T2 Esophageal Adenocarcinoma: A Multicenter Prospective Cohort Study. *Endoscopy*. 2021.

130. van de Ven SEM, Suzuki L, Gotink AW, Ten Kate FJC, Nieboer D, Weusten B, Brosens LAA, van Hillegersberg R, Alvarez Herrero L, Seldenrijk CA, Alkhalaf A, Moll FCP, Curvers W, van Lijnschoten IG, Tang TJ, van der Valk H, Nagengast WB, Kats-Ugurlu G, Plukker JTM, Houben M, van der Laan JS, Pouw RE, Bergman J, Meijer SL, van Berge Henegouwen MI, Wijnhoven BPL, de Jonge PJF, Doukas M, Bruno MJ, Biermann K, Koch AD. Lymphovascular Invasion Quantification Could Improve Risk Prediction of Lymph Node Metastases in Patients with Submucosal (T1b) Esophageal Adenocarcinoma. *United European Gastroenterol J.* 2021;9(9):1066-73.
131. van den Hoogen MWF, Seghers L, Manintveld OC, Roest S, Bekkers JA, den Hoed CM, Minnee RC, de Geus HRH, van Thiel RJ, Hesselink DA. Care for the Organ Transplant Recipient on the Intensive Care Unit. *J Crit Care.* 2021;64:37-44.
132. van der Bogt RD, van der Wilk BJ, Nikkessen S, Krishnadath KK, Schoon EJ, Oostenbrug LE, Siersema PD, Vleggaar FP, Doukas M, van Lanschot JJB, Spaander MCW. Predictive Value of Endoscopic Esophageal Findings for Residual Esophageal Cancer after Neoadjuvant Chemoradiotherapy. *Endoscopy.* 2021;53(11):1098-104.
133. van der Giessen J, Fuhler GM, van der Woude CJ. A First Pregnancy Seems Associated with a Positive Effect on the Course of Inflammatory Bowel Disease: Data from a Prospective Pregnancy Cohort. *Scand J Gastroenterol.* 2021;56(6):693-8.
134. van der Wiel SE, Stassen PMC, De Jong DM, Poley JW, de Jonge PJF, Bruno MJ. Pancreatoscopy-Guided Electrohydraulic Lithotripsy for the Treatment of Obstructive Pancreatic Duct Stones in the Head and Neck of the Pancreas: A Prospective Consecutive Case Series. *Gastrointest Endosc.* 2021.
135. van der Wilk BJ, Noordman BJ, Neijenhuis LKA, Nieboer D, Nieuwenhuijzen GAP, Sosef MN, Henegouwen M, Lagarde SM, Spaander MCW, Valkema R, Biermann K, Wijnhoven BPL, van der Gaast A, van Lanschot JJB, Doukas M, Nikkessen S, Luyer M, Schoon EJ, Roef MJ, van Lijnschoten I, Oostenbrug LE, Riedl RG, Gisbertz SS, Krishnadath KK, Bennink RJ, Meijer SL, Collaborators. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders after Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study. *Ann Surg.* 2021;274(6):1009-16.
136. van Dijk M, Brakenhoff SM, Isfordink CJ, Cheng WH, Blokzijl H, Boland G, Dofferhoff ASM, van Hoek B, van Nieuwkoop C, Sonneveld MJ, van der Valk M, Drenth JPH, de Knecht RJ. The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. *J Clin Med.* 2021;10(19).
137. van Eerden RAG, van Doorn L, de Man FM, Heersche N, Doukas M, van den Bosch TPP, Oomen-de Hoop E, de Bruijn P, Bins S, Ibrahim E, Nikkessen S, Friberg LE, Koolen SLW, Spaander MCW, Mathijssen RHJ. Tissue Type Differences in Abcb1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients with Esophageal Cancer. *Front Pharmacol.* 2021;12:759146.
138. van Erpecum KJ, Sonneveld MJ. Antiviral Therapy after Curative Treatment of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection: Is Tenofovir or Entecavir Preferred? *Eur J Intern Med.* 2021;89:27-9.
139. Van Hees S, Cuyppers B, Bourgeois S, Groothuisink ZMA, Meysman P, Van der Vlies P, de Knecht R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Sorted B Cell Transcriptomes Point Towards Actively Regulated B Cell Responses During Ongoing Chronic Hepatitis B Infections. *Cell Immunol.* 2021;362:104283.
140. van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, Janssen HLA, de Knecht RJ, Sonneveld MJ. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Risk of Adverse Outcomes in Patients with Chronic Hepatitis B. *JHEP Rep.* 2021;3(5):100350.
141. van Munster SN, Frederiks CN, Nieuwenhuis EA, Alvarez Herrero L, Bogte A, Alkhalaf A, Schenk BE, Schoon EJ, Curvers WL, Koch AD, van de Ven SEM, de Jonge PJF, Tang TJ, Nagengast WB, Peters FTM, Westerhof J, Houben M, Bergman J, Pouw RE, Weusten B. Incidence and Outcomes of Poor Healing and Poor Squamous Regeneration after Radiofrequency Ablation Therapy for Early Barrett's Neoplasia. *Endoscopy.* 2021.
142. van Munster SN, Nieuwenhuis EA, Weusten B, Herrero LA, Bogte A, Alkhalaf A, Schenk BE, Schoon EJ, Curvers W, Koch AD, van de Ven SEM, de Jonge PJF, Tang T, Nagengast WB, Peters FTM, Westerhof J, Houben M, Bergman J, Pouw RE, Dutch Barrett Expert C. Endoscopic Resection without Subsequent Ablation Therapy for Early Barrett's Neoplasia: Endoscopic Findings and Long-Term Mortality. *J Gastrointest Surg.* 2021;25(1):67-76.

143. van Munster SN, Verheij EPD, Nieuwenhuis EA, Offerhaus J, Meijer SL, Brosens LAA, Weusten B, Alkhalaf A, Schenk EBE, Schoon EJ, Curvers WL, van Tilburg L, van de Ven SEM, Tang TJ, Nagengast WB, Houben M, Seldenrijk KCA, Bergman J, Koch AD, Pouw RE, Dutch Barrett Expert C. Extending Treatment Criteria for Barrett's Neoplasia: Results of a Nationwide Cohort of 138 Endoscopic Submucosal Dissection Procedures. *Endoscopy*. 2021.
144. van Riet PA, Erler NS, Bruno MJ, Cahen DL. Comparison of Fine-Needle Aspiration and Fine-Needle Biopsy Devices for Endoscopic Ultrasound-Guided Sampling of Solid Lesions: A Systemic Review and Meta-Analysis. *Endoscopy*. 2021;53(4):411-23.
145. van Riet PA, Quispel R, Cahen DL, Erler NS, Snijders-Kruisbergen MC, Van Loenen P, Poley JW, van Driel L, Mulder SA, Veldt BJ, Leeuwenburgh I, Anten MGF, Honkoop P, Thijssen AY, Hol L, Hadithi M, Fitzpatrick CE, Schot I, Bergmann JF, Bhalla A, Bruno MJ, Biermann K. Optimizing Cytological Specimens of Eus-Fna of Solid Pancreatic Lesions: A Pilot Study to the Effect of a Smear Preparation Training for Endoscopy Personnel on Sample Quality and Accuracy. *Diagn Cytopathol*. 2021;49(2):295-302.
146. van Rosmalen BV, Furumaya A, Klompenhouwer AJ, Tushuizen ME, Braat AE, Reinten RJ, Ligthart MAP, Haring MPD, de Meijer VE, van Voorthuizen T, Takkenberg RB, Dejong CHC, de Man RA, JNM IJ, Doukas M, van Gulik TM, Verheij J, Dutch Benign Liver Tumor G, the Pg. Hepatocellular Adenoma in Men: A Nationwide Assessment of Pathology and Correlation with Clinical Course. *Liver Int*. 2021;41(10):2474-84.
147. Vermeulen BD, van der Leeden B, Ali JT, Gudbjartsson T, Hermansson M, Low DE, Adler DG, Botha AJ, D'Journo XB, Eroglu A, Ferri LE, Gubler C, Haveman JW, Kaman L, Kozarek RA, Law S, Loske G, Lindenmann J, Park JH, Richardson JD, Salminen P, Song HY, Soreide JA, Spaander MCW, Tarascio JN, Tsai JA, Vanuytsel T, Rosman C, Siersema PD, Benign Esophageal Perforation Collaborative G. Early Diagnosis Is Associated with Improved Clinical Outcomes in Benign Esophageal Perforation: An Individual Patient Data Meta-Analysis. *Surg Endosc*. 2021;35(7):3492-505.
148. Voskuil MD, Spekhorst LM, van der Sloot KWJ, Jansen BH, Dijkstra G, van der Woude CJ, Hoentjen F, Pierik MJ, van der Meulen AE, de Boer NKH, Lowenberg M, Oldenburg B, Festen EAM, Weersma RK. Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes. *J Crohns Colitis*. 2021;15(6):930-7.
149. Vuik FER, Moen S, Nieuwenburg SAV, Schreuders EH, Kuipers EJ, Spaander MCW. Applicability of Colon Capsule Endoscopy as Pan-Endoscopy: From Bowel Preparation, Transit, and Rating Times to Completion Rate and Patient Acceptance. *Endosc Int Open*. 2021;9(12):E1852-E9.
150. Vuik FER, Nieuwenburg SAV, Moen S, Spada C, Senore C, Hassan C, Pennazio M, Rondonotti E, Pecere S, Kuipers EJ, Spaander MCW. Colon Capsule Endoscopy in Colorectal Cancer Screening: A Systematic Review. *Endoscopy*. 2021;53(8):815-24.
151. Vuik FER, Nieuwenburg SAV, Nagtegaal ID, Kuipers EJ, Spaander MCW. Clinicopathological Characteristics of Early Onset Colorectal Cancer. *Aliment Pharmacol Ther*. 2021;54(11-12):1463-71.
152. Wagner A, Aretz S, Auranen A, Bruno MJ, Cavestro GM, Crosbie EJ, Goverde A, Jelsig AM, Latchford A, Leerdam MEV, Lepisto A, Puzzone M, Winship I, Zuber V, Moslein G. The Management of Peutz-Jeghers Syndrome: European Hereditary Tumour Group (Ehtg) Guideline. *J Clin Med*. 2021;10(3).
153. Ykema BLM, Bisseling TM, Spaander MCW, Moons LMG, van der Biessen-van Beek D, Saveur L, Kerst M, Mulder SF, de Wit R, Zweers D, Meijer GA, Beijnen JH, Lansdorp-Vogelaar I, van Leeuwen FE, Snaebjornsson P, van Leerdam ME. Diagnostic Yield of Colonoscopy Surveillance in Testicular Cancer Survivors Treated with Platinum-Based Chemotherapy: Study Protocol of a Prospective Cross-Sectional Cohort Study. *BMC Gastroenterol*. 2021;21(1):67.
154. Zhang X, Mens MMJ, Abozaid YJ, Bos D, Darwish Murad S, de Knecht RJ, Ikram MA, Pan Q, Ghanbari M. Circulatory Micrnas as Potential Biomarkers for Fatty Liver Disease: The Rotterdam Study. *Aliment Pharmacol Ther*. 2021;53(3):432-42.
155. Zhu F, Arshi B, Ikram MA, De Knecht RJ, Kavousi M. Sex-Specific Normal Values and Determinants of Infrarenal Abdominal Aortic Diameter among Non-Aneurysmal Elderly Population. *Sci Rep*. 2021;11(1):17762.



## **B Promotions in 2021**

1. 08-01-2021. Fiorella Murillo Perez. 21-01-2020. Louisa van Dijk. Prognostic factors for clinical outcome in patients with primary biliary cholangitis. Supervisors: H.J. Metselaar, H.L.A. Janssen. Co-supervisor: B.E. Hansen.
2. 27-01-2021. Joany Kreijne. Safety and Efficacy of Inflammatory Bowel Disease Treatment: a challenging balance. Supervisor: C.J. van der Woude. Copromotoren: A.C. de Vries, K.H.N. de Boer.
3. 12-05-2021. Jorn Goet. Risk stratification in primary biliary cholangitis and primary sclerosing cholangitis. Supervisor: H.J. Metselaar. Co-supervisors: B.E. Hansen, H.R. van Buuren.
4. 13-10-2021. Steffi van de Ven. Diagnosis and treatment of early esophageal carcinoma and second primary tumors in the upper aerodigestive tract. Supervisor: M.J. Bruno. Co-supervisor: A.D. Koch.
5. 16-11-2021. Jose Debes. Hepatocellular carcinoma: the interconnection of epidemiology, immunopathogenesis and treatment. Supervisor: R.A. de Man. Co-supervisor: A. Boonstra.
6. 17-11-2021. Janine van der Giessen. Pregnancy and Inflammatory Bowel Disease, perspectives from bench and bedside. Supervisors: C.J. van der Woude, M.P. Peppelenbosch. Copromotor: G.M. Fuhler.

## **C Events organized in 2021**

- 25-11-2021: 36th Erasmus Liver Day